The ANPEP Knouckout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population derived from the Jurkat human T-lymphoblast cell line, carrying a targeted disruption of the ANPEP gene locus. This pool of knockout cells serves as a versatile loss-of-function model for investigating the biological roles of CD13 (alanyl aminopeptidase) in T-cell biology, signal transduction, and disease-relevant processes.
Jurkat cells are an immortalized T-lymphocyte line originally established from the peripheral blood of a 14-year-old male with acute T-cell leukemia. Widely employed as a model for T-cell receptor signaling, activation, and apoptosis, Jurkat cells provide a robust and well-characterized background for studying leukemia-associated mechanisms. The availability of ANPEP knockout in this context enables researchers to dissect CD13 contributions specifically within a malignant T-cell environment.
ANPEP encodes CD13, a zinc-dependent metallopeptidase that cleaves N-terminal neutral amino acids from oligopeptides, modulating bioactivity of peptide hormones, chemokines, and opioid peptides like enkephalins. CD13 also acts as a coronavirus receptor and mediates cell adhesion via interactions with integrins (??v??3), galectin-3, and Fc?? receptors. Its expression is regulated by C/EBP, PU.1, AP-1, and NF-??B, and induced by TNF-??, IL-4, and TGF-??. Downstream, CD13-dependent processing of MCP-1 and other substrates influences RAS-ERK signaling through modulation of GRB2/SOS/RAF/MEK/ERK, while also intersecting with Wnt/??-catenin and FAK/Src pathways, thereby affecting proliferation and migration.
Disruption of ANPEP in Jurkat polyclonal knockout cells abrogates CD13 surface expression and enzymatic activity, providing a clean system to assess the impact on T-cell leukemia biology. The loss of CD13-mediated peptide trimming is expected to impair chemokine processing (e.g., MCP-1 cleavage), alter integrin-dependent adhesion and migration, and perturb RAS-ERK and Wnt/??-catenin pathway dynamics. Consequently, these cells are well-suited for dissecting how CD13 contributes to leukemic cell proliferation, survival, and metastatic potential, as well as for exploring its role as a coreceptor in coronavirus entry. The polyclonal nature of the knockout population offers a realistic representation of heterogeneous gene disruption effects, without relying on a single clonal genotype.
The ANPEP knockout Jurkat polyclonal cells are suited for a range of functional studies, including analysis of CD13-dependent signaling, chemokine and opioid peptide metabolism, and integrin-mediated adhesion. Researchers can confirm CD13 loss by Western blotting and flow cytometry, quantify enzymatic impairment via aminopeptidase assays, and monitor chemokine cleavage kinetics. Cell adhesion experiments, coronavirus infection assays, and ERK phosphorylation analyses further illuminate CD13??s impact on integrin and RAS-ERK pathways. Such tools facilitate drug target validation for aminopeptidase inhibitors and investigations into CD13??s involvement in acute myeloid leukemia, inflammatory diseases, and cancer metastasis. For further details, please contact Ascent Research.
